Therapeutics News and Research

RSS

Microglia transitions act as critical turning point in Alzheimer's

Researchers from VIB, KU Leuven, the UK-DRI and Muna Therapeutics, funded by, among others, ERC, have uncovered a critical biological transition that may determine whether Alzheimer's disease pathology leads to dementia.

4 Jun 2026

Industrial processing of food poses health risks beyond poor nutrition

Concerns about the health effects of ultra-processed foods are growing, as studies increasingly link them to conditions such as heart disease, diabetes, and even early death.

4 Jun 2026

Study potentially opens a new route to more selective cancer drug design

Researchers at the Icahn School of Medicine at Mount Sinai have identified a previously hidden druggable site in a cancer-related protein that could open the door toward the development of a new generation of more precise cancer drugs.

3 Jun 2026

New manufacturing platform produces targeted mixtures of beneficial gut bacteria

Researchers at the Icahn School of Medicine at Mount Sinai have developed a new manufacturing platform for producing targeted mixtures of beneficial gut bacteria, an approach that could help expand access to microbiome-based therapies for patients with recurrent Clostridioides difficile (C. difficile) infection.

3 Jun 2026

Acupuncture improves muscle function recovery in stroke patients

Paralysis on one side of the body is common after stroke. A new study in CNS Neuroscience & Therapeutics demonstrates that acupuncture can significantly improve muscle function recovery in patients who experienced a stroke, with this recovery correlating to increases in grey matter volume in certain regions of the brain related to cognitive-motor integration.

3 Jun 2026

Gladstone receives NIAID grant to establish the Center for PhAIge Therapy

When a bacterial infection stops responding to antibiotics, doctors have few options to treat it. Phages-viruses that naturally infect and kill bacteria-have long intrigued clinicians as a potential weapon against these infections.

2 Jun 2026

Allen Institute launches global research initiative to accelerate new treatments for brain disorders

The Allen Institute, together with partner organizations, today launched the Brain Health accelerator: an ambitious global research initiative seeking to identify the specific brain cells and circuits affected in neurodegenerative disease and other brain disorders and use that knowledge to accelerate the development of new treatments.

2 Jun 2026

Cross-reactive T cells target measles and dangerous Nipah viruses

T cells are some of the immune system's most important warriors. They can stop tumor growth and even fight off severe infections.

2 Jun 2026

New magnetic particle imaging ensures precision cell therapy injection tracking

Scientists at Johns Hopkins Medicine say they used a form of magnetic imaging to track cell therapy injections commonly used to treat certain autoimmune diseases and cancers.

2 Jun 2026

Deep brain stimulation rewires brain circuits linked to depression

Researchers from the Icahn School of Medicine at Mount Sinai have uncovered the first direct evidence that deep brain stimulation (DBS) can remodel white matter pathways in the brain and alter communication across large-scale neural networks, revealing a previously unrecognized mechanism that may explain how the therapy helps patients recover from severe depression.

1 Jun 2026

Pediatric experts reveal the 10 research areas set to shape child health

Pediatric research leaders identified 10 high-promise areas likely to shape child health over the next 5 to 10 years, including genomics, mental health, vaccines, artificial intelligence, perinatal medicine, precision therapeutics, health equity, nutrition, environmental health, and cancer treatment. The paper argues that these opportunities will only translate into better outcomes if pediatric research receives sustained funding, public trust, workforce support, advocacy, and equitable implementation.

1 Jun 2026

Laverock Therapeutics awarded in excess of £2.2 M through two innovation grants to support AI-powered platform development and to expand therapeutic programs outside of oncology

Laverock Therapeutics ('Laverock'), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, today announced it has been awarded two new grants totaling in excess of £2.2 M to support the next generation of its gene-control platform development, and expansion into additional non-oncology therapeutics areas.

From Laverock Therapeutics 1 Jun 2026

Gladstone scientists track exact routes used to clear brain waste

Think of the brain as if it were a house. Insulated from its environment, a house relies on complex networks-pipes, drains, and disposal systems-that interface with the outside world to keep the home functional on the inside.

29 May 2026

4basebio launches high-performance enzymatic ssDNA platform to accelerate next-generation gene editing

4basebio PLC, a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces the commercial launch of its high-capacity single-stranded DNA (ssDNA) product line to accelerate the development of safer, more precise genetic therapies by enabling targeted gene editing, advanced cell engineering, and innovative nucleic acid-based medicines.

From 4basebio PLC 29 May 2026

WHO prioritizes candidate vaccines and therapeutics for Bundibugyo virus

In response to the current outbreak of Ebola disease caused by Bundibugyo virus occurring in the Democratic Republic of the Congo, with cases also reported in Uganda, WHO convened several of its expert and advisory groups.

29 May 2026

Smokers undergoing lung cancer surgery face higher complication risks

Researchers at the University of Cincinnati College of Medicine have found that patients who continue to smoke ahead of lung cancer surgery have a higher risk of pulmonary complications, but their short-term mortality rate is similar to patients who were able to stop smoking before surgery.

28 May 2026

Brain transposons may influence aging and neurodegenerative disease progression

Transposable elements (TEs), also called transposons, are DNA sequences capable of moving or replicating from one location to another within a genome.

28 May 2026

Scientists identify new therapeutic target for deadly prostate cancer

Researchers at Columbia University Irving Medical Center have identified a gene that drives the development of neuroendocrine prostate cancer (NEPC), an aggressive form of the disease.

28 May 2026

New nutrient-sensing mechanism offers hope for neurodegenerative diseases

Researchers from the University of Cambridge highlight new ways that neurons and many cell types use to sense nutrients - opening potential novel therapeutic avenues for disorders such as Alzheimer's and Parkinson's disease.

28 May 2026

Traditional medicinal plant extract shows promising anti-skin aging effects

Announcing a new publication for Acta Materia Medica journal. Vicatia thibetica de Boiss (V. thibetica), a traditional medicinal and edible plant used by the Bai ethnic group in China, is known for its effects in tonifying qi, nourishing the blood, dispelling dampness, and relieving itching.

27 May 2026